Clinical practice guidelines for the management of dyslipidemia.
The causal relationship between dyslipidemia and atherosclerosis is well-documented. Screening and appropriate management of dyslipidemia by health care providers is imperative in both primary and secondary prevention of coronary artery disease, peripheral vascular disease, and stroke. In response to the release of new research data, clinical practice guidelines for the management of dyslipidemia in Canada have recently been updated. This article will provide an overview of the recommendations for screening, risk assessment, and target lipid values. Dietary and lifestyle interventions will be discussed in addition to pharmacotherapy as management strategies for achieving therapeutic lipid targets.
Nichols
Natalie
N
natalie.nichols@cdha.nshealth.ca
D002170:Canada / Q000453:epidemiology; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D018752:Diet, Fat-Restricted; D016903:Drug Monitoring / Q000379:methods / Q000592:standards; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000150:complications / Q000175:diagnosis* / Q000628:therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008019:Life Style; D008403:Mass Screening / Q000379:methods / Q000592:standards; D018579:Patient Selection; D017410:Practice Guidelines as Topic; D018570:Risk Assessment / Q000379:methods / Q000592:standards
D000960:Hypolipidemic Agents